Bathaix F, Marion D, Cuinet M, Maillard E, Zoulim F, Mornex F, Merle P
Liver Unit, Hôpital de l'Hôtel-Dieu, 69002 Lyon, France.
Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):314-8. doi: 10.1016/j.gcb.2010.01.015. Epub 2010 Mar 5.
Sorafenib has recently been approved as the gold standard therapy for advanced BCLC-C hepatocellular carcinomas. Although significant improvement of survival rates was shown, objective tumor response rates remained low following RECIST criteria in phases 2 and 3 studies. We report the rare case of a patient with a large hepatocellular carcinoma tumor invading suprahepatic veins in which sorafenib led to a very significant regression by about 90% of the tumor bulk, thus allowing at sterilizing the residual tumor tissue by subsequent combination of transarterial intrahepatic chemoembolization and high dose radiotherapy.
索拉非尼最近已被批准作为晚期BCLC-C期肝细胞癌的金标准疗法。尽管显示出生存率有显著提高，但在2期和3期研究中，根据RECIST标准，客观肿瘤缓解率仍然很低。我们报告了1例罕见的肝细胞癌大肿瘤侵犯肝上静脉的患者，索拉非尼使肿瘤体积显著缩小约90%，随后通过肝动脉内化疗栓塞和高剂量放疗联合应用消除了残留肿瘤组织。
